Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5

In recent years, successful examples of antisense oligonucleotide (AS) therapy for genetic diseases have stimulated scientists to investigate its application on cancer diseases. AS can be used to down‐regulate the mRNA and protein expression by annealing to specific region of the target mRNA which is responsible for the malignancy. Glucose transporter 5 (Glut5) is a tissue specific transporter that can be found on breast cancer tissues but not on normal breast tissues. Therefore, it is of clinical interest to investigate whether AS against Glut5 mRNA can tackle breast cancer. In this study, two cell lines, MCF‐7 which is estrogen‐receptor positive and MDA‐MB‐231 which is estrogen‐receptor negative, were used to mimic breast cancer tissues at early and late stages, respectively. A 15‐base sequence around the start codon of Glut5 was used. It was found that AS against Glut5 exerted anti‐proliferative effect on both of these two breast tumor cell lines and seemed to exert its effect via the suppression of expression of Glut5 proteins in the cells. AS against Glut5 exhibited no effect on human hepatoma HepG2 cells which do not possess any Glut5. The results imply an alternative way in treating breast tumor as the AS against Glut5, unlike tamoxifen, takes effect on breast tumor cells via suppressing the expression of Glut5 that they specifically possess, and regardless whether the breast tumors are estrogen dependent or not. © 2004 Wiley‐Liss, Inc.

[1]  J. Walker,et al.  Antisense Therapeutics , 2005, Methods in Molecular Medicine™.

[2]  I. S. Wood,et al.  Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins , 2003, British Journal of Nutrition.

[3]  K. Fung,et al.  Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 and MCF-7 Cells. , 2002, Bioconjugate chemistry.

[4]  K. Fung,et al.  Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdr1) antisense RNA. , 2000, Life sciences.

[5]  Y. Miyagi,et al.  Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. , 2000, Cancer letters.

[6]  R Kole,et al.  Modification of alternative splicing pathways as a potential approach to chemotherapy. , 2000, Pharmacology & therapeutics.

[7]  M. Gleave,et al.  Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. , 2000, Journal of the National Cancer Institute.

[8]  T. Oguri,et al.  Differential Expression of Facilitative Glucose Transporter (GLUT) Genes in Primary Lung Cancers and Their Liver Metastases , 1999, Japanese journal of cancer research : Gann.

[9]  M. Berridge,et al.  Transforming oncogenes regulate glucose transport by increasing transporter affinity for glucose: contrasting effects of oncogenes and heat stress in a murine marrow-derived cell line. , 1998, Life sciences.

[10]  D. Burstein,et al.  GLUT1 glucose transporter expression in colorectal carcinoma , 1998, Cancer.

[11]  R. Haas,et al.  Antisense strategies for the treatment of hematological malignancies and solid tumors , 1998, Annals of Hematology.

[12]  G. Damonte,et al.  Synthesis and characterization of a specific peptide nucleic acid that inhibits expression of inducible NO synthase , 1998, FEBS letters.

[13]  J. Baselga,et al.  Expression of the fructose transporter GLUT5 in human breast cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Brown,et al.  GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. , 1995, Anticancer research.

[15]  H. Yamamoto,et al.  Characterization of the rabbit intestinal fructose transporter (GLUT5). , 1994, The Biochemical journal.

[16]  D. Fingar,et al.  A role for Raf-1 in the divergent signaling pathways mediating insulin-stimulated glucose transport. , 1994, The Journal of biological chemistry.

[17]  R. Grobholz,et al.  Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis. , 1993, Cancer research.

[18]  M. Weber,et al.  Differential regulation of glucose transporter isoforms by the src oncogene in chicken embryo fibroblasts , 1991, Molecular and cellular biology.

[19]  Kazutomo Inoue,et al.  Over-expression of facilitative glucose transporter genes in human cancer. , 1990, Biochemical and biophysical research communications.

[20]  K. Fung,et al.  Glucose regulates its own transport in Ehrlich ascites tumour cells. , 1986, Biochemical and biophysical research communications.